{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:52:27Z","timestamp":1781646747620,"version":"3.54.5"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Hospital"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Familial Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    An increased lifetime risk of ovarian cancer is observed among women with a family history of ovarian cancer, with or without breast cancer, as well as among carriers of pathogenic germline variants in ovarian cancer (OC) predisposition genes. Over the past two decades, additional OC\u2013associated genes beyond\n                    <jats:italic>BRCA1\/2<\/jats:italic>\n                    have been identified, highlighting the need for updated genetic evaluation in women previously classified as high-risk without a known PV to ensure correct diagnosis and prevent overtreatment. This retrospective, quality assurance cohort study aimed to evaluate whether updated multigene panel sequencing and genetic counseling improve risk stratification. All women enrolled in the OC surveillance program at Copenhagen University Hospital Herlev between 2018 and 2023 and received counseling prior to the implementation of the revised 2017 guidelines in Denmark, were included. Among 674 women (median age 40.9), 174 had a\n                    <jats:italic>BRCA1<\/jats:italic>\n                    PV, 168 had a\n                    <jats:italic>BRCA2<\/jats:italic>\n                    PV, 55 had PVs in moderate-risk genes, and 277 were enrolled based on family history of OC\u2009\u00b1\u2009BC alone. Of these 277, 216 (78%) underwent updated genetic testing and counselling; 165 (76%) had no increased risk of OC and were released from gynecological surveillance. Over a mean follow-up of 48\u00a0months, none developed OC, and one developed BC, corresponding to a negative predictive value of 99% for the updated risk assessment. Updated genetic testing and counseling significantly improve risk stratification in women previously classified as increased risk of OC based solely on family history. This supports re-evaluation of at-risk women and families to guide appropriate surveillance, reduce unnecessary follow-up and interventions, and align clinical practice with evolving guidelines.\n                  <\/jats:p>","DOI":"10.1007\/s10689-026-00547-2","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T07:11:31Z","timestamp":1774595491000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Re-evaluating hereditary breast and ovarian cancer risk: clinical impact of updated multigene panel sequencing and genetic counseling"],"prefix":"10.1007","volume":"25","author":[{"given":"Julie Isabelle Plougmann","family":"Gislinge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Byrjalsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klara Vinsand","family":"Naver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helle Vibeke","family":"Clausen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pernille","family":"Ravn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kresten Rubeck","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin A. W.","family":"Wadt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,27]]},"reference":[{"key":"547_CR1","unstructured":"Nielsen HR, Skytte A-B, Blaak\u00e6r J (2019) National guideline for udredning af heredit\u00e6r disposition til ovariecancer, HOC"},{"issue":"23","key":"547_CR2","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1001\/jama.2017.7112","volume":"317","author":"KB Kuchenbaecker","year":"2017","unstructured":"Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ et al (2017) Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 317(23):2402\u20132416","journal-title":"JAMA"},{"issue":"3","key":"547_CR3","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1200\/OP.21.00382","volume":"18","author":"YL Liu","year":"2022","unstructured":"Liu YL, Breen K, Catchings A, Ranganathan M, Latham A, Goldfrank DJ et al (2022) Risk-reducing bilateral salpingo-oophorectomy for ovarian cancer: a review and clinical guide for hereditary predisposition genes. JCO Oncol Pract 18(3):201\u2013209","journal-title":"JCO Oncol Pract"},{"issue":"15","key":"547_CR4","doi-asserted-by":"publisher","first-page":"6789","DOI":"10.1002\/cam4.2534","volume":"8","author":"S Greenberg","year":"2019","unstructured":"Greenberg S, Buys SS, Edwards SL, Espinel W, Fraser A, Gammon A et al (2019) Population prevalence of individuals meeting criteria for hereditary breast and ovarian cancer testing. Cancer Med 8(15):6789\u20136798","journal-title":"Cancer Med"},{"issue":"12","key":"547_CR5","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1111\/j.1471-0528.2007.01499.x","volume":"114","author":"ER Woodward","year":"2007","unstructured":"Woodward ER, Sleightholme HV, Considine AM, Williamson S, McHugo JM, Cruger DG (2007) Annual surveillance by CA125 and transvaginal ultrasound for ovarian cancer in both high-risk and population risk women is ineffective. BJOG 114(12):1500\u20131509","journal-title":"BJOG"},{"issue":"1","key":"547_CR6","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.ygyno.2005.08.038","volume":"100","author":"RI Olivier","year":"2006","unstructured":"Olivier RI, Lubsen-Brandsma MA, Verhoef S, van Beurden M (2006) CA125 and transvaginal ultrasound monitoring in high-risk women cannot prevent the diagnosis of advanced ovarian cancer. Gynecol Oncol 100(1):20\u201326","journal-title":"Gynecol Oncol"},{"key":"547_CR7","unstructured":"Nielsen HR (2019) National guideline for udredning af heredit\u00e6r disposition til ovariecancer, HOC. DSOG Guideline"},{"issue":"8","key":"547_CR8","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1200\/JCO.2007.13.9626","volume":"26","author":"ND Kauff","year":"2008","unstructured":"Kauff ND, Domchek SM, Friebel TM, Robson ME, Lee J, Garber JE et al (2008) Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol 26(8):1331\u20131337","journal-title":"J Clin Oncol"},{"key":"547_CR9","unstructured":"Helle Vibeke Clausen, Forstholm Malene, Hassan Suher O, Kronschanbl Manuela, Mandrup Mette, Mikkelsen Maria, Mosgaard Berit, Nielsen Julie H, Profylaktisk kirurgin ved BRCA 1\u20132 og h\u00f8j risiko for arvelig ovariecancer. https:\/\/static1.squarespace.com\/static\/5467abcce4b056d72594db79\/t\/59ac4d64e5dd5b69d4126ec4\/1504464229771\/Profylaktisk+kirurgi+ved+brca.pdf"},{"issue":"13","key":"547_CR10","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1002\/cncr.29321","volume":"121","author":"JL Walker","year":"2015","unstructured":"Walker JL, Powell CB, Chen LM, Carter J, Bae Jump VL, Parker LP et al (2015) Society of Gynecologic Oncology recommendations for the prevention of ovarian cancer. Cancer 121(13):2108\u20132120","journal-title":"Cancer"},{"issue":"5","key":"547_CR11","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1136\/jmg-2022-108898","volume":"60","author":"H Hanson","year":"2023","unstructured":"Hanson H, Kulkarni A, Loong L, Kavanaugh G, Torr B, Allen S et al (2023) UK consensus recommendations for clinical management of cancer risk for women with germline pathogenic variants in cancer predisposition genes: RAD51C, RAD51D, BRIP1 and PALB2. J Med Genet 60(5):417\u2013429","journal-title":"J Med Genet"},{"issue":"11","key":"547_CR12","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1038\/ejhg.2014.16","volume":"22","author":"L Cast\u00e9ra","year":"2014","unstructured":"Cast\u00e9ra L, Krieger S, Rousselin A, Legros A, Baumann JJ, Bruet O et al (2014) Next-generation sequencing for the diagnosis of hereditary breast and ovarian cancer using genomic capture targeting multiple candidate genes. Eur J Hum Genet 22(11):1305\u20131313","journal-title":"Eur J Hum Genet"},{"issue":"9","key":"547_CR13","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/nrc.2016.72","volume":"16","author":"FC Nielsen","year":"2016","unstructured":"Nielsen FC, van Overeem Hansen T, S\u00f8rensen CS (2016) Hereditary breast and ovarian cancer: new genes in confined pathways. Nat Rev Cancer 16(9):599\u2013612","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"547_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100235","volume":"6","author":"M Bono","year":"2021","unstructured":"Bono M, Fanale D, Incorvaia L, Cancelliere D, Fiorino A, Cal\u00f2 V et al (2021) Impact of deleterious variants in other genes beyond BRCA1\/2 detected in breast\/ovarian and pancreatic cancer patients by NGS-based multi-gene panel testing: looking over the hedge. ESMO Open 6(4):100235","journal-title":"ESMO Open"},{"issue":"10","key":"547_CR15","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.22874","volume":"3","author":"GF Guzauskas","year":"2020","unstructured":"Guzauskas GF, Garbett S, Zhou Z, Spencer SJ, Smith HS, Hao J et al (2020) Cost-effectiveness of population-wide genomic screening for hereditary breast and ovarian cancer in the United States. JAMA Netw Open 3(10):e2022874","journal-title":"JAMA Netw Open"},{"issue":"8","key":"547_CR16","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1038\/s41436-018-0406-9","volume":"21","author":"A Lee","year":"2019","unstructured":"Lee A, Mavaddat N, Wilcox AN, Cunningham AP, Carver T, Hartley S et al (2019) BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors. Genet Med 21(8):1708\u20131718","journal-title":"Genet Med"},{"issue":"8","key":"547_CR17","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1038\/s41431-023-01380-2","volume":"31","author":"J Henkel","year":"2023","unstructured":"Henkel J, Laner A, Locher M, Wohlfrom T, Neitzel B, Becker K et al (2023) Diagnostic yield and clinical relevance of expanded germline genetic testing for nearly 7000 suspected HBOC patients. Eur J Hum Genet 31(8):925\u2013930","journal-title":"Eur J Hum Genet"},{"issue":"3","key":"547_CR18","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1007\/s00432-020-03377-6","volume":"147","author":"J Lerner-Ellis","year":"2021","unstructured":"Lerner-Ellis J, Mighton C, Lazaro C, Watkins N, Di Gioacchino V, Wong A et al (2021) Multigene panel testing for hereditary breast and ovarian cancer in the province of Ontario. J Cancer Res Clin Oncol 147(3):871\u2013879","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"547_CR19","doi-asserted-by":"publisher","first-page":"18629","DOI":"10.1038\/s41598-022-23012-3","volume":"12","author":"BP Matta","year":"2022","unstructured":"Matta BP, Gomes R, Mattos D, Olicio R, Nascimento CM, Ferreira GM et al (2022) Familial history and prevalence of BRCA1, BRCA2 and TP53 pathogenic variants in HBOC Brazilian patients from a public healthcare service. Sci Rep 12(1):18629","journal-title":"Sci Rep"},{"key":"547_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/ijms252312546","author":"P Nagy","year":"2024","unstructured":"Nagy P, Papp J, Grolmusz VK, Bozsik A, P\u00f3cza T, Ol\u00e1h E et al (2024) Comprehensive clinical genetics, molecular and pathological evaluation efficiently assist diagnostics and therapy selection in breast cancer patients with hereditary genetic background. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms252312546","journal-title":"Int J Mol Sci"},{"issue":"9","key":"547_CR21","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1136\/jmedgenet-2016-103800","volume":"53","author":"R Manchanda","year":"2016","unstructured":"Manchanda R, Legood R, Antoniou AC, Gordeev VS, Menon U (2016) Specifying the ovarian cancer risk threshold of \u201cpremenopausal risk-reducing salpingo-oophorectomy\u201d for ovarian cancer prevention: a cost-effectiveness analysis. J Med Genet 53(9):591\u2013599","journal-title":"J Med Genet"},{"issue":"3","key":"547_CR22","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.ygyno.2015.10.001","volume":"139","author":"R Manchanda","year":"2015","unstructured":"Manchanda R, Legood R, Pearce L, Menon U (2015) Defining the risk threshold for risk reducing salpingo-oophorectomy for ovarian cancer prevention in low risk postmenopausal women. Gynecol Oncol 139(3):487\u2013494","journal-title":"Gynecol Oncol"},{"issue":"1","key":"547_CR23","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1080\/13696998.2022.2152233","volume":"26","author":"S Teppala","year":"2023","unstructured":"Teppala S, Hodgkinson B, Hayes S, Scuffham P, Tuffaha H (2023) A review of the cost-effectiveness of genetic testing for germline variants in familial cancer. J Med Econ 26(1):19\u201333","journal-title":"J Med Econ"},{"issue":"2","key":"547_CR24","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1002\/cncr.26294","volume":"118","author":"MD Schwartz","year":"2012","unstructured":"Schwartz MD, Isaacs C, Graves KD, Poggi E, Peshkin BN, Gell C et al (2012) Long-term outcomes of BRCA1\/BRCA2 testing: risk reduction and surveillance. Cancer 118(2):510\u2013517","journal-title":"Cancer"},{"issue":"12","key":"547_CR25","doi-asserted-by":"publisher","DOI":"10.1002\/pon.70054","volume":"33","author":"JIP Gislinge","year":"2024","unstructured":"Gislinge JIP, Byrjalsen A, Naver KV, Clausen HV, Ravn P, Petersen KR et al (2024) Living a cancer surveillance life: a meta-ethnographic synthesis of everyday experiences and ambivalences for women living with hereditary risk of breast and\/or ovarian cancer. Psychooncology 33(12):e70054","journal-title":"Psychooncology"},{"key":"547_CR26","unstructured":"J\u00f8nsson AB, Brodersen JB (2022) Snart er vi alle patienter - Overdiagnostik i medicinske og samfundsfaglige perspektiver. Samfundslitteratur"},{"key":"547_CR27","unstructured":"Brodersen JB (2023) Overdiagnostik: Et negligeret og ul\u00f8st problem i diagnostikken. Ugeskrift for L\u00e6ger"},{"issue":"4","key":"547_CR28","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1080\/09513590.2021.1871894","volume":"37","author":"S Javadpour","year":"2021","unstructured":"Javadpour S, Sharifi N, Mosallanezhad Z, Rasekhjahromi A, Jamali S (2021) Assessment of premature menopause on the sexual function and quality of life in women. Gynecol Endocrinol 37(4):307\u2013311","journal-title":"Gynecol Endocrinol"},{"issue":"1","key":"547_CR29","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1093\/jsxmed\/qdad143","volume":"21","author":"N Zilski","year":"2023","unstructured":"Zilski N, Speiser D, Bartley J, Roehle R, Blohmer JU, Keilholz U et al (2023) Quality of life after risk-reducing salpingo-oophorectomy in women with a pathogenic BRCA variant. J Sex Med 21(1):33\u201339","journal-title":"J Sex Med"}],"container-title":["Familial Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10689-026-00547-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10689-026-00547-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10689-026-00547-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:58:53Z","timestamp":1781643533000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10689-026-00547-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,27]]},"references-count":29,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["547"],"URL":"https:\/\/doi.org\/10.1007\/s10689-026-00547-2","relation":{},"ISSN":["1573-7292"],"issn-type":[{"value":"1573-7292","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,27]]},"assertion":[{"value":"26 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"35"}}